Sobi is a leading integrated biopharmaceutical company that focuses on developing therapies and treatments for haemophilia, inflammation, genetic and metabolic diseases. Its operations are split into three core areas: Core Products, Partner Products and ReFacto Manufacturing. The organisation spans 24 countries, delivering therapies to patients in 67 countries across the globe. However, Europe accounts for up to 54 per cent of its sales. Sobi is headquartered in Stockholm, Sweden.